Innate Pharma S.A. - American Depositary Shares (IPHA) earnings
IPHA earnings moved a median of +1.42% by the close. Quarterly and annual IPHA reports and results, each read against the price at its own news timestamp. Back to the IPHA overview →
13 measured IPHA earnings events.
Where these IPHA earnings landedvs 12 measured IPHA earnings reactions
| Middle 50% of IPHA earnings reactions | -1.60% to +3.70% |
|---|---|
| Median reaction (to close) | +1.42% |
| Measured reactions | 12 |
Point-in-time · zero look-ahead
Half of the 12 IPHA earnings events with a measured close landed between -1.60% and +3.70%; 67% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update | Press release | — | +7.35% | |
| Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | Press release | +0.00% | -6.38% | |
| Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report | Press release | +0.00% | +1.48% | |
| Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | Press release | -3.61% | — | |
| Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | Press release | +0.00% | +0.00% | |
| Innate Pharma Reports First Quarter 2025 Business Update and Financial Results | Press release | +0.00% | -12.07% | |
| Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F | Press release | — | +1.36% | |
| Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results | Press release | — | -8.94% | |
| Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates | Press release | — | +6.63% | |
| Innate Pharma Reports First Quarter 2024 Business Update and Financial Results | Press release | — | +2.72% | |
| Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F | Press release | +0.00% | +1.71% | |
| Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update | Press release | — | +7.50% | |
| Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update | Press release | -3.54% | +1.18% |
Keep exploring
More IPHA: analyst actions → · SEC filings → · IPHA overview →